-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...
More »SEARCH RESULT
Total Matching Records found : 288
Indian drug makers face heat of US regulator's crackdown-Sushmi Dey
-The Business Standard Data also show that several other leading domestic pharma companies have recalled their products from the US Frequent drug recalls, warning letters and import alerts from the US in the recent past have turned into a major concern for the Indian pharmaceutical industry and investors. While Ranbaxy Laboratories recently pleaded guilty before the US authorities for its wrongdoings in the past, the crackdown on the drug companies seems to...
More »Who Manufactures Dirty Medicines?-Amit Sengupta
-Newsclick.in A few weeks back Fortune magazine and CNN carried a long online blog titled ‘Dirty Medicine' by Dinesh Thakur, a former employ of Ranbaxy, where he recounts how he came across several procedural and other lapses in the company's manufacturing facilities. Since then the Fortune blog has become one of the most widely circulated and commented upon business stories in the world. The story received attention as it came in the...
More »Spectre of drug shortage over TB treatment -Rupali Mukherjee
-The Times of India MUMBAI: The treatment of lakhs of tuberculosis (TB) patients, especially children, across the country has been jeopardized over the past few weeks as India battles a severe shortage of key TB drugs. The stock-outs are more to do with two categories: paediatric and drug-resistant TB or DR-TB, industry experts say. Medical experts say that unless the government intervenes immediately, such acute shortage of drugs could prove disastrous for...
More »We trust indian manufacturing norms: USFDA -Divya Rajagopal
-The Economic Times MUMBAI: The United States Food and Drug Administration (USFDA), widely considered the world's most stringent regulatory authority, has said India's share in generic exports to the US over the years is an indication of the good manufacturing norms practised by Indian drugmakers. As the Ranbaxy scandal threatens to tarnish India's image as a hub of manufacturing world-class generic drugs, the statement, by USFDA's spokesman Chris Kelly in an...
More »
